|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
|
|
gptkbp:administeredBy
|
gptkb:tablet
oral suspension
|
|
gptkbp:affects
|
elevated liver enzymes
|
|
gptkbp:approved_in_country
|
gptkb:India
gptkb:Japan
gptkb:Russia
|
|
gptkbp:ATCCode
|
J05AX27
|
|
gptkbp:brand
|
gptkb:Avigan
gptkb:Covifor
gptkb:FabiFlu
|
|
gptkbp:CASNumber
|
259793-96-9
|
|
gptkbp:chemicalClass
|
gptkb:pyrazinecarboxamide
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Toyama_Chemical
|
|
gptkbp:discovered_in_decade
|
2000s
|
|
gptkbp:discoveredBy
|
gptkb:Japan
|
|
gptkbp:eliminationHalfLife
|
2 to 5.5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
YWHUANSKBGJZLX-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C5H4FN3O2
|
|
gptkbp:hasSMILES
|
C1=CN=C(C(=O)N)C(=O)N1F
|
|
gptkbp:hasUNII
|
EW5GL2X7E0
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Favipiravir
|
|
gptkbp:IUPACName
|
gptkb:6-fluoro-3-hydroxy-2-pyrazinecarboxamide
|
|
gptkbp:KEGGID
|
D09902
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
gptkb:aldehyde_oxidase
|
|
gptkbp:molecularWeight
|
157.10 g/mol
|
|
gptkbp:not_approved_by
|
gptkb:US_FDA
|
|
gptkbp:pregnancyCategory
|
contraindicated
|
|
gptkbp:PubChem_CID
|
431952
492405
CHEMBL2028663
DB12466
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
teratogenicity
hyperuricemia
|
|
gptkbp:synonym
|
gptkb:T-705
|
|
gptkbp:used_in_clinical_trials_for
|
gptkb:COVID-19
gptkb:Ebola_virus_disease
gptkb:Lassa_fever
|
|
gptkbp:usedFor
|
gptkb:COVID-19
influenza
|
|
gptkbp:year_of_approval_in_Japan
|
2014
|
|
gptkbp:bfsParent
|
gptkb:West_African_Ebola_epidemic
gptkb:Ebola_outbreak_in_West_Africa
|
|
gptkbp:bfsLayer
|
6
|